Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


Our top-notch dedicated system is used to design specialised libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
Q9UJ41

UPID:
RABX5_HUMAN

ALTERNATIVE NAMES:
RAP1; Rabaptin-5-associated exchange factor for Rab5; Rabex-5

ALTERNATIVE UPACC:
Q9UJ41; B4DZM7; Q3HKR2; Q3HKR3; Q53FG0

BACKGROUND:
Rab5 GDP/GTP exchange factor, known alternatively as RAP1, Rabaptin-5-associated exchange factor for Rab5, and Rabex-5, is integral to cellular trafficking and membrane dynamics. It serves as a critical effector for Rab proteins, specifically linking gamma-adaptin with RAB4A or RAB5A. Its involvement in the fusion of endocytic membranes and the trafficking of recycling endosomes is vital for cellular homeostasis. The protein's ability to stimulate nucleotide exchange on RAB5A and function as a ubiquitin ligase highlights its multifunctional role in cellular processes.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of Rab5 GDP/GTP exchange factor could open doors to potential therapeutic strategies.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.